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Abstract
Background: [18F] fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG-PET/CT)
may be used for tumor staging and prognosis in several tumors but its role in rectal cancer is still debated. The aim
of the present study was to assess the correlation of baseline [18F] FDG-PET parameters with tumor staging, tumor
response (tumor regression grade (TRG)), and outcome in a series of patients affected by locally advanced rectal
cancer (LARC) treated with neoadjuvant chemoradiotherapy (CRT).
Methods: One hundred patients treated with neoadjuvant CRT and radical surgery were enrolled in the present
study. Maximum standardized uptake value (SUVmax), SUVmean, metabolic tumor volume (MTV), and total lesion
glycolysis (TLG) at the baseline [18F] FDG-PET were calculated. These PET parameters were correlated with tumor
staging, histopathological data (TRG1 vs. TRG2–5 and TRG1–2 vs. TRG3–5), disease-free survival, and overall survival.
Results: SUVmax and SUVmean of primary tumor were statistically associated with T4-stage. SUVmax, SUVmean,
and TLG did not result statistically associated with TRG (TRG1 or TRG1–2). MTV resulted statistically associated with
TRG1–2 group (OR 2.9; 95% CI 1.2–7.1). Finally, no PET parameter was significantly associated with disease-free or
overall survival.
Conclusion: Our results showed that baseline [18F] FDG-PET parameters correlated with tumor staging, and only MTV
correlated with TRG 1–2. PET parameters failed to predict disease-free and overall survival after treatment completion.
The results leave open to further studies the issue of identifying patients suitable for conservative approaches.
Keywords: Rectal cancer, [18F] fluorodeoxyglucose positron emission tomography, Standardized uptake value,
Metabolic tumor volume, Total lesion glycolysis, Predictive value
Background
Treatment approach to rectal cancer has greatly evolved
over the past years. In locally advanced rectal cancer
(LARC), neoadjuvant chemoradiotherapy (CRT) followed
by surgical resection with total mesorectal excision is the
current standard treatment approach [1, 2].
According to literature data, 50 to 60% of the patients
can reach a down-staging following CRT with about 20%
of complete pathological response [3]. This rate of patho-
logical response has raised the issue of organ preservation.
Notably, Habr-Gama et al. [4] pioneered this innovative
concept by avoiding surgery when a complete response
was achieved at restaging after CRT. The study reported
49% of complete clinical response after CRT in a series of
183 patients with T2–4 N0–2 distal rectal tumors. Subse-
quently, the “watch and wait” strategy or the local excision
after CRT has been explored as organ-preserving
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alternatives in selected patients’ cohorts with encouraging
results [5, 6].
Tumor response after CRT is usually assessed by the
tumor regression grade (TRG) as proposed by Mandard
et al. [7], based on the pathological exam of the surgical
specimen. Nowadays, the diagnostic challenge for an
organ preservation approach is to find an adequate sur-
rogate of histology able to discriminate responders from
non-responders. The attention on morphological (i.e.
magnetic resonance imaging, MRI) and even more on
metabolic imaging suitable for predicting CRT response
is constantly increasing [8, 9]. In this regard, the role
that [18F] -fluorodeoxyglucose positron emission tomog-
raphy/computed tomography ([18F] FDG-PET/CT) has
in staging and treatment planning of rectal cancer is still
quite debatable [10–12] as well as in measuring treat-
ment response [13–18].
The primary aim of the present study was to evaluate
whether in LARC metabolic characteristics detected by
[18F] FDG-PET/CT, prior to neoadjuvant CRT, could
correlate with clinical tumor stage, with tumor regres-
sion after surgery, and with MRI findings. A secondary
endpoint was to determine the prognostic value of [18F]
FDG-PET/CT in terms of disease-free survival (DFS)
and overall survival (OS).
Methods
Patients
From 2008 to 2016, one hundred patients were enrolled
in the present observational study after obtaining a writ-
ten informed consent following the rules of our institu-
tion. The local ethics committee approved the present
study. Inclusion criteria were as follows: biopsy proven
rectal adenocarcinoma, age > 18 years, cT3–4 cN0–2
disease at staging, absence of distant metastasis or other
concomitant tumors, no contraindication to chemother-
apy, and availability of the [18F] FDG-PET/CT images
retrieved from our institutional digital archive. All cases
were discussed in a multidisciplinary conference with
gastroenterologists, surgeons, radiation oncologists, and
medical oncologists.
Pre-treatment workup included blood chemistry, clin-
ical examination, endoscopy with biopsy, and chest and
abdomen CT. Tumor extension and lymph-nodal in-
volvement were assessed by pelvic MRI on a 1.5 Tesla
scanner (Achieva, Philips Medical System, Best, Holland)
and [18F] FDG-PET/CT [8]. Final staging was defined
according to the American Joint Committee on Cancer
(AJCC) TNM classification [19]. The main clinical char-
acteristics of patients are listed in Table 1.
[18F] FDG-PET/CT imaging
The patients underwent [18F] FDG-PET/CT within five
working days from CT simulation by hybrid PET/CT
scanner (Biograph 16 HI-REZ, Siemens Medical Solutions,
Berkeley CA), equipped with Pico-3D digital electronics
and reconstruction with ordered subset expectation
maximization (OSEM3D) algorithm (2 iterations × 24 sub-
sets, and a post-reconstruction Gaussian filter with a full
width at maximum of 8 mm), on a 256 × 256 image frame
(voxel size 2.66 mm× 2.66 mm× 2.00 mm). Images were
analyzed using a dedicated workstation Leonardo (Siemens
Medical Solutions, Berkeley CA). CT images were used for
both attenuation correction of PET data and localization of
pathological FDG uptake. CT scan was performed without
administration of intravenous contrast with a low-dose
protocol for CT acquisition. Fasting time was at least 6 h
prior to examination. The blood glucose levels of all pa-
tients were measured before the injection of [18F] FDG
and were < 150 mg/dL. The injected activity of FDG was
3 MBq/Kg and the mean time between injection and
Table 1 Patients’ clinical characteristics
Characteristics Value (%)
Gender (No. of patients)
Male 65 (65.0)
Female 35 (35.0)
Age (years)
Median 67
Range 41–83
Tumor clinical stage (No. of patients)
cT3 85 (85.0)
cT4 15 (15.0)
Nodal clinical stage (No. of patients)
cN0 32 (32.0)
cN+ 68 (68.0)
Rectal segment, distance to the anal verge
Upper third 20 (20.0)
Middle third 42 (42.0)
Lower third 38 (38.0)
Pathological stage (No. of patients)
ypT0 N0 16 (16.0)
ypT1 N0-N1 5 (5.0)
ypT2 N0-N2 19 (19.0)
ypT3 N0-N1-N2 56 (56.0)
ypT4 N0-N1-N2 4 (4.0)
TRG (No. of patients)
TRG 1 16 (16.0)
TRG 2 15 (15.0)
TRG 3 25 (25.0)
TRG 4 22 (22.0)
TRG 5 22 (22.0)
No number, TRG Tumor regression grade
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acquisition was 70 min (range: 55–90 min). [18F]
FDG-PET/CT imaging was performed from the proximal
femur to the base of the skull. Emission images were ac-
quired for 2–5 min per bed position, depending on patient’s
body mass index as described in a previous study [20].
The processed images were displayed in coronal,
transverse, and sagittal plans and interpreted in standard
clinical fashion, both separately and in fused mode. The
[18F] FDG-PET/CT images were reviewed for abnormal
FDG uptake of the primary tumor, lymph nodes, and
distant sites. The maximum standardized uptake value
(SUVmax) was calculated for each primary tumor, along
with the mean standardized uptake value (SUVmean),
the metabolic tumor volume (MTV) and the total lesion
glycolysis (TLG) according to the European Agency of
Nuclear Medicine (EANM) guidelines [21].
The SUVmax was automatically calculated to determine
the [18F] FDG-PET activity and recorded using a volumet-
ric region of interest (VOI), positioned around the patho-
logical [18F] FDG uptake in the attenuation-corrected
images. Each VOI was checked visually to exclude areas of
physiological uptake as bladder. The MTV was defined as
the volume of hypermetabolic tissue with a threshold
greater than 41% of the maximum pixel value in the pri-
mary tumor [21]. The software calculated the SUVmean
within the MTV. The TLG was defined as the SUVmean
multiplied by the MTV.
Treatment
All patients were treated with neoadjuvant CRT. External
beam RT was delivered by Linear accelerators (Varian
Clinac 600 DBX and Varian Clinac DHX, Varian Medical
Systems, Milpitas CA) to a total dose of 45 Gy, with daily
fraction of 1.8 Gy. RT was given to all patients in a homo-
geneous way including the identification of the clinical tar-
get volume (CTV) which was defined as the gross tumor
volume with the mesorectal fascia and the pelvic lymph
nodes as recommended by Roels et al. [22]. An isotropic
expansion of 8 mm around the CTV was applied to define
the planning target volume (PTV). Treatment planning
(Pinnacle, Philips, Adac Laboratories, Milpitas CA) was
performed through 3-dimension-conformal RT (3D-CRT)
technique in 57 patients and by “step and shot” intensity
modulated radiotherapy (IMRT) in 43 patients. In the
present study, [18]F FDG-PET/CT imaging was used for
both tumor staging, and target identification as reported
in a previous study [8]. Concomitant chemotherapy was
administered during the five weeks of RT with daily oral
capecitabine (825 mg/m2 twice daily) or continuous infu-
sion of 5-fluorouracil (225 mg/m2).
After CRT, all patients were re-staged with the same
imaging modality (CT/MRI) performed for baseline
tumor staging, in particular 42 patients were re-staged
with MRI (TSE T2 weighted and post-contrast weighted
TFE T1 sequences). A total mesorectal excision with
anterior or abdominoperineal resection was performed
6–11 weeks (median 8 weeks) after CRT according to
the clinical presentation.
Clinical endpoints
Data was collected to evaluate metabolic parameters de-
tected by [18F] FDG-PET/CT prior to neoadjuvant CRT
in relation with pre-treatment tumor characteristics (i.e.
tumor extension, distance from the anal verge, and pres-
ence of pathological lymph-nodes), treatment response,
response assessment with MRI, and survival.
Post-surgical staging was assessed according to the AJCC/
TNM classification (ypTNM) [19]. A pathological finding of
ypT0N0 was considered a complete pathological response,
while any ypT1–4 N0–2 a non-complete pathological re-
sponse (Table 1). These findings were scored according to
TRG classification following the criteria defined by Mandard
et al. [7]: TRG1 = complete tumor response, no residual
cancer cell; TRG2= residual cancer cells scattered through
fibrosis; TRG3 = increased number of residual cancer cells
with predominant fibrosis; TRG4= residual cancer outgrow-
ing fibrosis; and TRG5 = no regressive changes within the
tumor. We performed the analysis between TRG1 and
TRG2–5 and between TRG1–2 and TRG3–5.
In the subset of 42 patients who repeated MRI after
neoadjuvant treatment (TSE T2 weighted, post-contrast
weighted TFE T1 sequences), the response assessment,
scored by Response Evaluation Criteria in Solid Tumors
(RECIST) [23] was compared with PET parameters.
During follow-up, patients underwent the same exams
as at baseline every 6 months for the first 2 years and
then every year. Diagnosis of recurrent tumor and dis-
tant metastasis was based on clinical and radiological
evidence of tumor relapse, confirmed by biopsy.
Statistical analysis
All quantitative PET imaging parameters (SUVmax,
SUVmean, MTV, and TLG) were expressed as mean ±
standard deviation (SD). The student 2-tailed t-test after
normalization using logarithmic transformation was
used to compare the quantitative parameters of the clin-
ical variables categorized as follows: cT3 vs. cT4, TRG1
vs. TRG2–5, and TRG1–2 vs. TRG3–5.
Binary logistic regression was performed to evaluate
the association of SUV, MTV and TLG with TRG using
the median value as cut-off. The odds ratios (OR) and
the 95% confidence interval (95% CI) were calculated.
The analysis of variance (ANOVA) after normalization
using logarithmic transformation was performed to
evaluate PET parameters differences among upper, mid-
dle and lower rectal cancer locations. Mann Whitney
test was performed to analyze the time interval from the
end of CRT and surgery among TRG classes.
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Logistic regression was applied to analyze and com-
pare PET and MRI images at restaging.
Follow-up time was analyzed from the last day of CRT
to the date of the last follow-up, recurrence, or death. DFS
and OS rates were calculated using Kaplan-Meier analysis
stratified according to cut-off value (median value) and
compared using the log-rank test. Recurrent and
non-recurrent patients were compared with Fisher test.
The statistical power of the study was 50%. This was cal-
culated on 100 patients enrolled, on value of alpha equal to
0.05, and on the 4-years OS for SUVmax median value as
cut-off equal to 0.90 (for patients with a SUVmax < 20.6)
and to 0.75 (for patients with a SUVmax > 20.6). A p value
≤0.05 was considered as statistically significant. Statistical
analysis was performed using STATA v11 (Stata Corpor-
ation, College Station, TX, USA).
Results
Metabolic characteristics in relation to clinical stage
and restaging
The mean values and SD of SUVmax, SUVmean, MTV,
and TLG of the baseline [18F] FDG-PET/CT were reported
in Table 2. The SUVmax (p = 0.01), SUVmean (p = 0.01),
MTV (p = 0.003) and TLG (p = 0.0004) values were signifi-
cantly higher in the cT4 than in the cT3 cases. Conversely,
PET parameters were not influenced by rectal tumor origin
in the upper, middle and lower rectum. By logistic regres-
sion model, primary tumors with SUVmax or SUVmean
higher than median values were statistically associated with
cT4-stage (both ORs 8.4; 95% CI 1.8–39.7).
Response assessment with MRI was available in 42 pa-
tients out of 100. None of the PET parameters resulted
statistically associated with MRI findings (1 complete re-
sponse and 20 partial responses vs. 11 stable diseases).
Pathological response evaluation
All patients underwent surgery with total mesorectal exci-
sion 6–8 weeks after CRT; anterior resection was performed
in 79 patients (79%) and abdominoperineal resection in 21
patients (21%). The ypTNM classification was available for
all the 100 patients (Table 1). At pathological examination,
16 patients (16%) were classified as TRG1 (ypT0 N0) and 84
(84%) as TRG2–5 (ypT1–4 N0–2). Sixty-one out of 100 pa-
tients (61%) achieved tumor downstaging. Negative margins
were observed in all but two patients, classified as TRG3
and TRG5 respectively, after neoadjuvant CRT.
Comparing [18F] FDG-PET parameters of TRG1 and
TRG2–5 no significant difference was found, but comparing
TRG1–2 and TRG3–5 MTV significantly changed (14.8 vs.
24.4, p= 0.01). Thus, only MTV resulted statistically associ-
ated withTRG1–2 group (OR 2.9; 95% CI 1.2–7.1) (Table 3).
Analyzing interval time between the last day of CRT
and surgery, no significant differences were observed
between TRG1 and TRG2–5 (p = 0.49) or TRG1–2 and
TRG3–5 (p = 0.30).
Metabolic characteristics in relation to DFS and OS
The median follow-up time of the whole series was
32 months (range 12–116 months). Twenty-four
patients (24%) developed loco-regional or at distance
relapse. Although all but one of them were classified
as TRG2–5 at the histological analysis, the compari-
son of tumor relapses between TRG1 and TRG2–5
did not achieve a statistical significance (p = 0.1). Ten
patients developed a loco-regional recurrence (41.7%)
and 14 liver and/or lung metastasis (58.3%). At the
time of analysis, 8 patients were dead (8%), 6 out of
the 8 died of metastatic progression disease. More-
over, none PET parameters significantly correlated
with DFS or OS (Figs. 1 and 2).
Discussion
It is well recognized that neoadjuvant CRT for LARC
has an impact on tumor downsizing and can achieve
a higher percentage of long-term local control and
better quality of life than adjuvant CRT [24]. More-
over, the achievement of a complete pathological re-
sponse has a demonstrated positive prognostic impact
on disease control [25]. Nowadays, the challenge is
how to discriminate responders from non-responders
to preoperative CRT, in order to tailor the treatment
strategy. Less aggressive surgery or “watch and wait”
policy after CRT for responders or more aggressive
treatment for non-responders. In this setting, the
most appropriate imaging approach to assess tumor
response is a key point and it is still matter of inves-
tigation. In this regard, endorectal ultrasounds and
MRI are routinely used for re-staging before surgical
procedure, but these imaging modalities suffer of lim-
ited accuracy in distinguishing residual tumor from
post-treatment changes such as fibrosis [26]. Of note,
some authors [27–30] investigated the early prediction
of tumor response based on [18F] FDG-PET/CT im-
aging performed during and after neoadjuvant CRT
by comparing the baseline [18F] FDG-PET with that
ad interim and before surgery. They observed that
tumor response was predicted by metabolic changes
in the first two weeks of RT, proving that [18F]
Table 2 [18F] FGD-PET parameters of the primary tumor
Variable Mean (SD) Minimum Maximum
SUVmax 22.7 (9.7) 5.7 54.1
SUVmean 13.2 (5.7) 3.1 32.6
MTV 21.4 (21.9) 1.2 153.9
TLG 313.0 (480.0) 8.0 3331.0
SD Standard deviation, SUVmaxMaximum standardized uptake value, SUVmeanMean
standardized uptake value,MTVMetabolic tumor volume, TLG Total lesion glycolysis
Deantonio et al. Radiation Oncology          (2018) 13:211 Page 4 of 9
FDG-PET/CT can be useful to predict pathological
response for rectal cancer. A weakness of these stud-
ies [27–30] was related to the small sample size of
patients that could have biased the results.
Our observational study analyzed whether the only
pretreatment [18F] FDG PET/CT could be correlated
with tumor stage and predict tumor response and
survival in a relatively large number of patients.
Because the choice of the best PET parameter to be
used is still debatable, in addition to the most
frequently used parameters (i.e. SUVmax and SUV-
mean), we decided to investigate also MTV and TLG
which are be able to predict treatment response in
other tumor types [31, 32].
In our study, a higher level of metabolic and volumet-
ric parameters was significantly associated with cT4
stage, generally considered a more aggressive disease.
Although the median baseline SUV, MTV, and TLG
showed higher values in TRG2–5 than TRG1, the
absence of a significant difference seems to support the
conclusion that the baseline [18F] FDG-PET parameters
cannot predict the achievement of rectal cancer
complete regression after neoadjuvant CRT. We also
considered PET parameters in the light of MRI response
assessment in a subset of 42 patients and we were not
able to find any significant association with tumor
response detected by MRI performed before surgery. In
this regard, a future study could consider the use of
Table 3 [18F] FGD-PET/CT parameters related to clinical variables
Variables cT stage Mean ± SD TRG Mean ± SD TRG Mean ± SD
cT3 cT4 TRG1 TRG2–5 TRG1–2 TRG3–5
SUVmax 21.6 ± 9.3 28.9 ±9.8 22.9 ±9.9 21.7 ±8.8 22.9 ±8.9 21.7 ± 10
p = 0.01 p = 0.68 p = 0.75
SUVmean 12.6 ± 5.5 16.6 ± 5.7 13.3 ± 5.9 12.5 ± 4.9 13.5 ± 5.4 13.3 ± 5.9
p = 0.01 p = 0.68 p = 0.6
MTV 18.0 ± 13.2 41.0 ± 43.2 22.4 ± 23.3 16.7 ± 11.7 14.8 ± 10.3 24.4 ± 24.9
p = 0.003 p = 0.21 p = 0.01
TLG 221.1 ± 172.6 833.5 ± 1053.0 330.1 ± 515.4 222.9 ± 200.8 210.6 ± 183.9 358.9 ± 560
p = 0.0004 p = 0.23 p = 0.08
T Tumor stage, TRG Tumor regression grade, SD Standard deviation, SUVmax Maximum standardized uptake value, SUVmean Mean standardized uptake value,
MTV Metabolic tumor volume, TLG Total lesion glycolysis, p p- value calculated with Student T-test
Fig. 1 4-years disease-free survival (DFS). Kaplan-Meier curves with the Log-Rank value of the PET parameters (SUVmax, SUVmean, TLG, and MTV) using
the median values as cut-off. The blue lines correspond to values higher than median, the red lines correspond to values lower than the median
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PET/MRI, including also DWI sequences, in the attempt
to optimize the response assessment.
Exploring the hypothesis that baseline[18F]
FDG-PET parameters might be able to predict
patients with a complete pathologic response, who
may be treated with organ preserving strategies, we
compared either TRG1 vs. TRG2–5 or TRG1–2 vs.
TRG3–5. As a matter of fact, only TRG1 cases repre-
sent true complete responses in which a transanal
endoscopic resection or a wait and see policy could
be justified. However, MTV resulted predictive of
tumor response only when TRG1–2 was compared to
TRG3–5. In this regard, only few studies [26, 33–35]
analyzed the predictive value of baseline [18F]
FDG-PET parameters with contrasting results, leaving
this issue still open for further investigation. Chennu-
pati et al. [33] did not find any correlation between
pathological response and SUVmax or MTV at base-
line in 35 patients who underwent [18F] FDG-PET.
Similar findings on 88 patients were reported by Park
el al. [26] who found no differences of the
pre-treatment [18F] FDG-PET parameters (SUV or
MTV) between responder and non-responder groups.
In contrast, Bang et al. [34] in a sample of 74
patients found that MTV calculated using different
thresholds was significantly associated with TRG1–2,
however this association was not confirmed after
multivariate analysis. Moreover, Hatt et al. [35] found
that response to CRT in a small sample of 28 patients
was correlated with higher levels of SUVmean (p =
0.02) but not with TLG and MTV.
Considering the survival findings, we have not ob-
served any significant correlation of [18F] FDG-PET
parameters with DFS or OS (Figs. 1, and 2). However,
all but one patient, who experienced a loco-regional
or at distance progression, were observed in the
non-responder group. Most likely, the low number of
tumor relapses could have influenced the non-signifi-
cance of the correlation of PET parameters with sur-
vival. In this regard, literature studies reported only
some and contrasting data on the correlation between
PET parameters and survival. Bang et al. [34] re-
ported that baseline MTV calculated with various
thresholds was significantly associated with 3-year
DFS, while Leccisotti et al. [36], analyzing baseline
post-treatment metabolic changes, did not find any
correlation with DFS or OS because of the very low
rate of tumor relapses after a median follow-up time
of 68 months.
As shown by our study and by the other literature
series, the predictive role of [18] FDG-PET is still
unclear and deserves further investigation (Table 4).
Although the present study has the limitation of a rela-
tively low statistical power, most likely related to the
low number of tumor relapses, it analyzed quite a large
number of patients treated in a homogeneous way at
the same institution and observed for quite a long
follow-up time.
Fig. 2 4-years overall survival (OS). Kaplan-Meier curves with the Log-Rank value of the PET parameters (SUVmax, SUVmean, TLG, and MTV) using
the median values as cut-off. The blue lines correspond to values higher than median, the red lines correspond to values lower than the median
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Conclusions
This study describes one of the largest series analyzing
baseline [18] FDG-PET parameters in LARC. The results
showed that SUVmax and SUVmean correlated with
tumor staging at diagnosis, and MTV was predictive of
tumor response. However, no parameter was predictive of
true complete response (TRG1). Moreover, none of the
analyzed parameters was able to predict DFS and OS.
The issue of identifying patients suitable for conserva-
tive approaches is still open, and different schedules of
imaging studies, including repeated PET after neoadju-
vant CRT, should be explored more deeply in the view
of a true personalized treatment modality.
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Table 4 Comparison among principal clinical series and our series
Study Number of patients Pathological
responders % (TRG)
PET parameter Correlation PET
with pCR p Value
Correlation PET
with DFS/OS
Martoni 2011
[15]
80 20% (TRG4 by Dworak) SUVmax pre
SUVmax post
Negative p = 0.05
Negative p = 0.0003
Disease recurrence: SUVmax
post >/< 5 p = 0.0003
Calvo 2013
[16]
38 50% (TRG3–4 by Dworak) SUVmax pre
SUVmax post
Negative p = 0.12
Negative p < 0.0001
ΔSUVmax< 4 risk of
Recurrence p = 0.0007
ΔSUVmax< 4 HR = 5.73
p = 0.05
Park 2014
[26]
88 19.3% (TRG1 by Mandard) SUVmax pre
SUVmax post
MTV pre
MTV post
NS
p < 0.001
p = 0.029
p < 0.0001
NA
Dos Anjos
2016 [28]
90 22.2% (TRG NA) ΔSUVmax (40%)
ΔMTV (40%)
ΔTLG (40%)
p < 0.0001
p = 0.005
p = 0.03
NA
Janssen
2012 [30]
26
20
42.3%(TRG1–2 by Mandard)
20% (TRG1–2 by Mandard)
RI SUVmax 48% SUVmax:
Spec 100%
Sens 64%
Spec 93%
Sens 83%
NA
Chennupati
2012 [33]
35 40% (TRG 0–1 by Ryan) SUVmax pre
MTV pre
SUVmax post
MTV post
ΔSUVmax
ΔMTV
NS
NS
NS
NS
NS
NS
NA
Bang 2016
[34]
74 23% (TRG 0–1 by AJCC) SUVmax pre
SUVpeak pre
SUVmean pre + 2 SDs
NS
NS
negative p = 0.0045
3-years DFS NS
3-years DFS NS
3-years DFS p = 0.01
Leccisotti
2015 [36]
126 24.6% (TRG1 by Mandard) Early RI SUVmax
Late RI SUVmax
Cut-off 61% p < 0.001
cut-off not found
10.3% local recurrences
4.8% deaths
Our series 100 16% (TRG1 by Mandard)
31% (TRG1–2 by Mandard)
SUVmax pre
SUVmean pre
MTV pre
TLG pre
SUVmax pre
SUVmean pre
MTV pre
TLG pre
NS
NS
NS
NS
NS
NS
p = 0.01
NS
4-years DFS NS
4-years OS NS
pCR Pathological complete response, TRG Tumor regression grade, RI Response index, Spec Specificity, Sens sensibility, Δ indicates percent residual, pre Before
radiochemotherapy, post After radiochemotherapy, SD Standard deviation, SUVmax Maximum standardized uptake value, SUVmean Mean standardized uptake
value, MTV Metabolic tumor volume, TLG Total lesion glycolysis, AJCC American Joint Committee on Cancer, NS Not significant, NA Not available
Deantonio et al. Radiation Oncology          (2018) 13:211 Page 7 of 9
Authors’ contributions
Conception and design: MK and LD. Provision of study materials or patients:
LD, AC, FA and LT. Collection and assembly of data: LD, EP, AC, and FA. Data
analysis and interpretation: LD, DF, EP and MK. Manuscript writing: All
authors. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study has been approved by the local ethics committee and has
therefore been performed according to the ethical standards laid down in
the 1964 Declaration of Helsinki and its later amendments. Patients were
required to provide written informed consent to participate in this research.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Radiotherapy, University Hospital “Maggiore della Carità”, Novara, Italy.
2Department of Translational Medicine, University of “Piemonte Orientale”,
Novara, Italy. 3Nuclear Medicine, University Hospital “Maggiore della Carità”,
Novara, Italy. 4Department of Translational Medicine, Unit of Medical
Statistics and Cancer Epidemiology, CPO Piemonte and University of
“Piemonte Orientale”, Novara, Italy. 5Medical Physics, University Hospital
“Maggiore della Carità”, Novara, Italy.
Received: 23 April 2018 Accepted: 11 October 2018
References
1. Sauer R, Liersch T, Merkel S, Fietkau R, et al. Preoperative versus
postoperative Chemoradiotherapy for locally advanced rectal Cancer: results
of the German CAO/ARO/AIO-94 randomized phase III trial after a median
follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.
2. Ciria JP, Eguiguren M, Cafiero S, et al. Could preoperative short-course
radiotherapy be the treatment of choice for localized advanced rectal
carcinoma? Rep Pract Oncol Radiother. 2015;20:1–11.
3. O’Neill BD, Brown G, Heald RJ, Cunningham D, Tait DM. Nonoperative
treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet
Oncol. 2007;8:625–33.
4. Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP. Local recurrence after
complete clinical response and watch and wait in rectal cancer after
neoadjuvant chemoradiation: impact of salvage therapy on local disease
control. Int J Radiat Oncol Biol Phys. 2014;88:822–8.
5. Appelt AL, Pløen J, Harling H, et al. High-dose chemoradiotherapy and
watchful waiting for distal rectal cancer: a prospective observational study.
Lancet Oncol. 2015;16:919–27.
6. Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical
T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local
excision (ACOSOG Z6041): results of an open-label, single-arm, multi-
institutional, phase 2 trial. Lancet Oncol. 2015;16:1537–46.
7. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF.
Pathologic assessment of tumor regression after preoperative
chemoradiotherapy of esophageal carcinoma. Clinicopathologic
correlations. Cancer. 1994;73:2680–6.
8. Denecke T, Rau B, Hoffmann KT, et al. Comparison of CT, MRI and FDG-PET
in response prediction of patients with locally advanced rectal cancer after
multimodal preoperative therapy: is there a benefit in using functional
imaging? Eur Radiology. 2005;15:1658–66.
9. Lambrecht M, Deroose C, Roels S, et al. The use of FDG-PET/CT and
diffusion-weighted magnetic resonance imaging for response prediction
before, during and after preoperative chemoradiotherapy for rectal cancer.
Acta Oncol. 2010;49:956–63.
10. Bassi MC, Turri L, Sacchetti G, et al. FDG-PET/CT imaging for staging and
target volume delineation in preoperative conformal radiotherapy of rectal
cancer. Int J Radiat Oncol Biol Phys. 2008;70:1423–6.
11. Krengli M, Cannillo B, Turri L, et al. Target volume delineation for preoperative
radiotherapy of rectal cancer: inter-observer variability and potential impact of
FDG-PET/CT imaging. Technol Cancer Res Treat. 2010;9:393–8.
12. Di Genesio Pagliuca M, Turri L, Munoz F, et al. Patterns of practice in the
radiation therapy management of rectal cancer: survey of the interregional
group Piedmont, Valle d’Aosta and Liguria of the “Associazione Italiana di
Radioterapia Oncologica (AIRO)”. Tumori. 2013;99:61–7.
13. van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation
of a predictive model for pathological complete response of rectal cancer patients
including sequential PET-CT imaging. Radiother Oncol. 2011;98:126–33.
14. Yeung JM, Kalff V, Hicks RJ, et al. Metabolic response of rectal cancer
assessed by 18-FDG PET following chemoradiotherapy is prognostic for
patient outcome. Dis Colon Rectum. 2011;54:518–25.
15. Martoni AA, Di Fabio F, Pinto C, Castellucci P, Pini S, Ceccarelli C.
Prospective study on the FDG-PET/CT predictive and prognostic values
in patients treated with neoadjuvant chemoradiation therapy and
radical surgery for locally advanced rectal cancer. Ann Oncology. 2011;
22:650–6.
16. Calvo F, Sole CV, de la Mata D, et al. (18)F-FDG PET/CT-based treatment
response evaluation in locally advanced rectal cancer: a prospective validation
of long-term outcomes. Eur J Nucl Med Mol Imaging. 2013;40:657–67.
17. Deantonio L, Milia ME, Cena T, et al. Anal cancer FDG/PET standard uptake
value: correlation with tumor characteristics, treatment response and
survival. Radiol Med. 2016;121:54–9.
18. Alongi F, Fersino S, Mazzola R, et al. Radiation dose intensification in pre-
operative chemo-radiotherapy for locally advanced rectal cancer. Clin Transl
Oncol. 2017;19:189–96.
19. Edge SB, Byrd DR, Compton CC, et al., editors. AJCC cancer staging manual,
7th edn. New York: Springer; 2010.
20. Brambilla M, Matheoud R, Secco C, et al. Impact of target-to-background
ratio, target size, emission scan duration, and activity on physical figures of
merit for a 3D LSO-based whole body PET/CT scanner. Med Phys. 2007;34:
3854–65.
21. Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM
procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol
Imaging. 2015;42:328–54.
22. Roels S, Duthoy W, Haustermans K, et al. Definition and delineation of the
clinical target volume for rectal cancer. Int J Radiation Oncology Biol Phys.
2006;65:1129–42.
23. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria
in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;
45(2):228–47.
24. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis
of outcomes following pathological complete response to neoadjuvant
chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–28.
25. García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD,
Rothenberger DA. A pathologic complete response to preoperative
chemoradiation is associated with lower local recurrence and improved
survival in rectal cancer patients treated by mesorectal excision. Dis Colon
Rectum. 2003;46:298–304.
26. Park J, Chang KJ, Seo YS, et al. Tumor SUVmax normalized to liver uptake
on 18F-FDG PET/CT predicts the pathologic complete response after
neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Nucl
Med Mol Imaging. 2014;48:295–302.
27. Maffione AM, Chondrogiannis S, Capirci C, et al. Early prediction of response
by 18F-FDG PET/CT during preoperative therapy in locally advanced rectal
cancer: a systematic review. Eur J Surg Oncol. 2014;40:1186–94.
28. Dos Anjos DA, Perez R, Habr-Gama A, et al. Semiquantitative volumetry by
sequential PET/CT may improve prediction of complete response to
neoadjuvant chemoradiation in patients with distal rectal cancer. Dis Colon
Rectum. 2016;59:805–12.
29. Cascini GL, Avallone A, Delrio P, et al. 18F-FDG PET is an early predictor of
pathologic tumor response to preoperative radiochemotherapy in locally
advanced rectal cancer. J Nucl Med. 2006;47:1241–8.
30. Janssen MH, Ollers MC, Riedl RG, et al. Accurate prediction of pathological
rectal tumor response after two weeks of preoperative radiochemotherapy
using (18)F-fluorodeoxyglucose-positron emission tomographycomputed
tomography imaging. Int J Radiat Oncol Biol Phys. 2010;77:392–9.
31. Bazan JG, Koong AC, Kapp DS, et al. Metabolic tumour volume predicts
disease progression and survival in patients with squamous cell carcinoma
of the anal canal. J Nucl Med. 2013;54:27–32.
Deantonio et al. Radiation Oncology          (2018) 13:211 Page 8 of 9
32. Lee P, Bazan JG, Lavori PW, et al. Metabolic tumor volume is an
independent prognostic factor in patients treated definitively for non-small-
cell lung cancer. Clin Lung Cancer. 2012;13:52–8.
33. Chennupati SK, Quon A, Kamaya A, et al. Positron emission tomography for
predicting pathologic response after neoadjuvant chemoradiotherapy for
locally advanced rectal cancer. Am J Clin Oncol. 2012;35:334–9.
34. Bang JI, Ha S, Kang SB, et al. Prediction of neoadjuvant radiation chemotherapy
response and survival using pretreatment [18F]FDG PET/CT scans in locally
advanced rectal cancer. Eur J Nucl Med Mol Imaging. 2016;43:422–31.
35. Hatt M, van Stiphout R, le Pogam A, et al. Early prediction of pathological
response in locally advanced rectal cancer based on sequential 18F-FDG
PET. Acta Oncol. 2013;52:619–26.
36. Leccisotti L, Gambacorta MA, de Waure C, et al. The predictive value of 18F-
FDG PET/CT for assessing pathological response and survival in locally
advanced rectal cancer after neoadjuvant radiochemotherapy. Eur J Nucl
Med Mol Imaging. 2015;42:657–66.
Deantonio et al. Radiation Oncology          (2018) 13:211 Page 9 of 9
